LINC Earnings

LINC reported its FY2025Q4 earnings on 2026-02-27, showcasing a revenue of 0.00 against an estimate of 132.00M, resulting in a 0% surprise. The EPS was 0, surpassing the expected 0.42 by 0% . The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following LINC's FY2025Q4 earnings announcement on 2026-02-27, the stock price moved by % on the day of the release. Over the subsequent five days, it saw a % change. Historically, LINC's stock price tends to shift by an average of -4.95% in the 10 days leading up to earnings and -2.50% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate LINC’s annual revenue to reach 132.00M, while the EPS is projected at 0.00. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Upward by 2.54% and EPS estimates Revise Upward by 1.49% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between LINC's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Upward by 2.54%, while EPS estimates moved Revise Upward by 1.49% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, LINC's stock price typically moves by -4.95% in the 10 days before its earnings and -2.50% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of 0.00 and revenue of 132.00M.

The earnings call summary and Q&A reveal strong financial metrics, optimistic guidance, and strategic growth plans, including new campus developments and program expansions. Despite some vague responses, the company's raised revenue and EBITDA guidance, alongside a robust student start growth forecast, indicate positive sentiment. The absence of regulatory hurdles and a focus on healthcare program improvements further support a positive outlook. The lack of market cap data suggests a conservative prediction, but overall, the company's strategic initiatives and financial health point towards a positive stock price movement in the short term.